TABLE 2.

Susceptibilities of gram-positive pathogens to the TEST panel of antimicrobial agents^a

Strain and antimicrobial	MIC (μg/ml)			% S	% I	% R
	50%	90%	Range
Methicillin-susceptible Staphylococcus aureus (n = 813)
Tigecycline	0.12	0.12	0.015-0.5	100	—d	—d
Penicillin	8	≥16	≤0.06-≥16	13.9	—e	86.1
Ampicillin	4	≥32	≤0.06-≥32	15.9	—e	84.1
Amoxicillin-clavulanate	1	2	≤0.03-4	100	—e	0.0
Piperacillin-tazobactam	1	2	≤0.25-8	100	—e	0.0
Imipenem	0.25	0.25	≤0.12-2	100	0.0	0.0
Ceftriaxone	4	4	0.12-32	96.9	3.1	0.0
Levofloxacin	0.12	4	≤0.06-≥64	87.6	2.3	10.1
Minocycline	≤0.25	≤0.25	≤0.25-8	99.0	1.0	0.0
Linezolid	2	2	≤0.5-4	100	—e	—e
Vancomycin	0.5	1	≤0.12-4	100	0.0	0.0
Methicillin-resistant Staphylococcus aureus (n = 879)
Tigecycline	0.12	0.25	0.03-0.5	100	—d	—d
Penicillin	≥16	≥16	0.25-≥16	0.0	—e	100
Ampicillin	≥32	≥32	0.5-≥32	0.0	—e	100
Amoxicillin-clavulanate	8	≥16	1-≥16	25.1b	—e	74.9
Piperacillin-tazobactam	16	≥32	1-≥32	31.9b	—e	68.1
Imipenem	0.5	16	≤0.12-≥32	82.6	3.8	13.7
Ceftriaxone	32	≥128	8-≥128	0.2	58.5	41.3
Levofloxacin	16	≥64	≤0.06-≥64	18.5	2.3	79.2
Minocycline	≤0.25	0.5	≤0.25-≥16	99.3	0.6	0.1
Linezolid	2	4	≤0.5-4	100	—e	—e
Vancomycin	1	1	0.25-4	100	0.0	0.0
Enterococcus faecalis (n = 740)
Tigecycline	0.06	0.12	0.015-0.5	—c	—d	—d
Penicillin	2	4	0.12-≥16	97.2	—e	2.8
Ampicillin	1	1	0.12-≥32	97.8	—e	2.2
Amoxicillin-clavulanate	0.5	1	≤0.03-≥16	—e	—e	—e
Piperacillin-tazobactam	2	4	≤0.25-≥32	—e	—e	—e
Imipenem	1	1	≤0.12-≥32	—e	—e	—e
Ceftriaxone	≥128	≥128	0.5-≥128	—e	—e	—e
Levofloxacin	1	≥64	≤0.06-≥64	55.3	1.1	43.6
Minocycline	8	8	≤0.25-≥16	44.2	46.2	9.6
Linezolid	2	2	≤0.5-16	97.6	1.9	0.5
Vancomycin	1	2	≤0.12-≥64	94.6	0.7	4.7
Enterococcus faecium (n = 280)
Tigecycline	0.06	0.12	0.015-0.5	—d	—d	—d
Penicillin	≥16	≥16	0.12-≥16	11.4	—e	88.6
Ampicillin	≥32	≥32	0.12-≥32	13.9	—e	86.1
Amoxicillin-clavulanate	≥16	≥16	0.06-≥16	—e	—e	—e
Piperacillin-tazobactam	≥32	≥32	1-≥32	—e	—e	—e
Imipenem	≥32	≥32	0.25-≥32	—e	—e	—e
Ceftriaxone	≥128	≥128	2-≥128	—e	—e	—e
Levofloxacin	≥64	≥64	0.5-≥64	8.9	1.4	89.6
Minocycline	0.5	8	≤0.25-≥16	67.9	23.9	8.2
Linezolid	2	2	≤0.5-4	96.4	3.6	0.0
Vancomycin	≥64	≥64	0.25-≥64	31.4	0.7	67.9
Streptococcus agalactiae (n = 655)
Tigecycline	0.03	0.25	0.015-1	99.5	—d	—d
Penicillin	≤0.06	0.12	≤0.06-0.25	99.8	—e	—e
Ampicillin	0.12	0.12	≤0.06-0.25	100	—e	—e
Amoxicillin-clavulanate	0.06	0.12	≤0.03-1	—e	—e	—e
Piperacillin-tazobactam	≤0.25	≤0.25	≤0.25-2	—e	—e	—e
Imipenem	≤0.12	0.25	≤0.12-1	—e	—e	—e
Ceftriaxone	0.06	0.12	≤0.03-2	99.8	—e	—e
Levofloxacin	0.5	1	≤0.06-32	99.4	0.5	0.2
Minocycline	8	≥16	≤0.25-≥16	—e	—e	—e
Linezolid	1	1	≤0.5-2	100	—e	—e
Vancomycin	0.5	0.5	≤0.12-1	100	—e	—e

^aS, susceptible; I, intermediate; R, resistant. Susceptible, intermediate, and resistant values may add to 99.9 or 100.1 due to rounding.

^bFor methicillin-resistant S. aureus, β-lactam/β-lactamase inhibitor combinations may appear active in vitro but are not effective clinically (8).

^cThe FDA-approved interpretive criteria for tigecycline and E. faecalis apply only to vancomycin-susceptible isolates.

^dNo FDA-approved interpretive criteria are available.

^eNo CLSI-approved interpretive criteria are available.